Atherogenics atherogenics.com


Public lists: Pharma Startups (4732)

AtheroGenics is an emerging pharmaceutical company, focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as heart disease (atherosclerosis), asthma and arthritis. Based on a proprietary drug discovery technology platform called vascular protectant technology, the company designed its lead product candidate, AGI-1067, to benefit patients with coronary artery disease, which is atherosclerosis of the blood vessels of the...Show all

AtheroGenics is an emerging pharmaceutical company, focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as heart disease (atherosclerosis), asthma and arthritis. Based on...Show all

Company (Alive / Active)

Phone: 678-336-2500

Fax:

8995 Westside Parkway

Alpharetta, 30009
Georgia, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Atherogenics $58.4M Jun 25, 2001
See all 70 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Atherogenics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 20 investors

Competitors

Company Status Description Investors

ActivBiotics

Lexington, Massachusetts, United States
Dead / InactiveActivBiotics is focused on the development and commercialization of antibacterials for the treatment of acute and chronic disease. The Company is developing rifalazil - a potent broad spectrum antibiotic that targets and inhibits the transcriptional machinery of bacteria.Login to see details

GlycoMimetics

Gaithersburg, Maryland, United States
IPO / Went publicGlycoMimetics is developing small molecule drugs that mimic the actions of carbohydrates using glycobiology. The company is focusing its initial efforts on therapeutics to treat inflammatory diseases such as cystic fibrosis and cancer.Login to see details
See all 70 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)